Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
What Needs to Happen Before California Pharmacies Can Sell PrEP and PEP Without an Initial Prescription
Pharmacists will increasingly play a role in pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) access in California.
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.
This inspiring moment from the U.S. Conference on AIDS illustrates how relationships can produce results for advocates.
Sept. 12, 2019: Better virologic outcomes at coordinated walk-in facilities offering incentives; same-day PrEP initiation at STD clinics; U=U and "low drug regimens"; adherence trends among perinatally infected adolescents.
Aug. 29, 2019: Viral load blips, low-level viremia, and eventual virologic failure; pinpointing non-adherence as a cause of HIV treatment failure; HIV care costs vary widely throughout U.S.; Kaposi sarcoma incidence in the modern HIV treatment era.
Nonjudgmental services and innovative ways to talk to youth about sex should be at the core of any sexual health plan.
Will potential study participants choose a vaccine trial over getting access to PrEP?